RE: "Interim Results - H1 24: profitability up, costs reduced"31 Jan 2024 12:42
Broker 30th Jan
In-line revenue growth and strong OpEx control Kromek reported interim results with revenues up 5% to £7.1m, adjusted EBITDA loss of ca. £0.1m, period-end gross cash of £3.7m and net debt of £5.2m. The company reiterated its view that fiscal 2024E revenues are expected to grow in-line with market expectations, which we see at around 20%, which implies a sharp pick-up in the H2 result (to +32%). Although this sounds a tough target it needs to be remembered that, because of the recurring contract revenue nature of the business, revenue forecasts are predictable – per the release management has good visibility on 84% of the 2024E forecast, with the remaining 16% to come from the known pipeline of opportunities. Adjusted EBITDA saw a dramatic improvement over H1 2023 at a loss of £0.1m, a function of the improving gross margin and significant control of other operating costs, which reduced from £8.0m to £6.4m. We slightly increase our 2024E, adjusted EBITDA moving from £0.9m to £1.2m, and more materially in 2025E, from £1.7m to £3.1m, driven by our belief that the company will continue to stay on top of operating costs. We see 2024E year-end gross cash at £3.5m and net debt at £5.4m (prior to £2.6m conversion of CLN). Having reviewed the longerterm opportunities for CZT in the Advanced Imaging market we increase our price target from 25p to 28p.